| Literature DB >> 33647824 |
Xue Wen1, Xingli Zhang2, Siji Nian3, Gang Wei4, Xiyuan Guo5, Hong Yu6, Xiang Xie7, Yingchun Ye8, Qing Yuan9.
Abstract
The lungs are directly connected to the external environment, which makes them more vulnerable to infection and injury. They are protected by the respiratory epithelium and immune cells to maintain a dynamic balance. Both innate and adaptive immune cells are involved in the pathogenesis of lung diseases. Mucosal-associated invariant T (MAIT) cells are a subset of unconventional T cells, which have attracted increasing attention in recent years. Although MAIT cells account for a small part of the total immune cells in the lungs, evidence suggests that these cells are activated by T cell receptors and/or cytokine receptors and mediate immune response. They play an important role in immunosurveillance and immunity against microbial infection, and recent studies have shown that subsets of MAIT cells play a role in promoting pulmonary inflammation. Emerging data indicate that MAIT cells are involved in the immune response against SARS-CoV-2 and possible immunopathogenesis in COVID-19. Here, we introduce MAIT cell biology to clarify their role in the immune response. Then we review MAIT cells in human and murine lung diseases, including asthma, chronic obstructive pulmonary disease, pneumonia, pulmonary tuberculosis and lung cancer, and discuss their possible protective and pathological effects. MAIT cells represent an attractive marker and potential therapeutic target for disease progression, thus providing new strategies for the treatment of lung diseases.Entities:
Keywords: Asthma; COVID-19; Inflammation; Mucosa-associated invariant T cells
Year: 2021 PMID: 33647824 PMCID: PMC7909906 DOI: 10.1016/j.intimp.2021.107485
Source DB: PubMed Journal: Int Immunopharmacol ISSN: 1567-5769 Impact factor: 4.932
Fig. 1MAIT cell characteristics, activation and function in immunity. MAIT cells are unconventional cells that express semi-invariant TCRs that recognize antigens presented by MHC-like molecule MR1. MAIT cells exist in the lungs in a stable state. MAIT cells express several key transcription factors such as T-bet, RORγt, PLZF, several tissue-homing cytokines receptors and markers. Upon bacterial, fungal or viral infection, MAIT cells can be activated in a TCR-dependent manner and/or in a TCR-independent cytokine-mediated manner by inflammatory cytokines like IL-12 and IL-18. In response, they secret Th1 type cytokines (IFN-γ, TNF-α) and Th17 type cytokines (IL-17A, IL-22), release granzyme B and perforin to dissolve infected cells. IFN-γ, interferon-γ; IL, interleukin; MAIT cell, mucosal-associated invariant T cell; MR1, MHC-related protein 1; PLZF, promyelocytic leukemia zinc finger; RORγt, retinoic-acid-related orphan receptor γt; TCR, T-cell receptor; TNF-α, tumor necrosis factor-α.
Distribution and frequency of MAIT cells in human and mouse tissue.
| Tissue distribution | Human | Mouse |
|---|---|---|
| Peripheral Blood | 1~10% | ~0.1% |
| Liver | 20~45% | ~0.6% |
| Lung | 2~4% | ~3% |
| Intestine | 1~10% | ~0.7% |
| Lymphoid tissue | <1% | ~0.2% |
| Thymus | <0.05% | <0.1% |
| Spleen | not detection | ~0.1% |
| Adipose tissue | 4~14% | ~2% |
MAIT cells in lung diseases.
| Disease | Frequency | Phenotype | Function | Reference |
|---|---|---|---|---|
| Asthma | in blood↓, | in blood MAIT-17/IL-4R↑ | in blood IL-17A/IL4I1↑ | |
| COPD | in blood↓ | in blood DN/CD8+ MAIT↓ | in blood IFN-γ↑ | |
| Pneumonia | ||||
| CAP | in blood↓, | in blood CD69/CD103↑ | in blood IL-17A/MCP-1↑,IFN-γ/IL-22↓ | |
| COVID-19 | in blood↓, | in blood CD69/PD-1/CD38/Ki67/HLA-DR↑, CXCR3↓ | in blood IL-1β/IL-6/IL-1RA/ IL-18/ IL-17A/Granzyme B↑, IFN-γ↓ | |
| TB | ||||
| Activated TB | in blood↓, | in blood CD69↑/↓, CD127/HLA-DR/CCR6/CD25/ | in blood IFN-γ↑/↓, TNF-α/IL-17F/IL-23/granzyme B/granulysin↓ | |
| Latent TB | in blood↑ | ND | in blood IFN-γ↑ | |
| Sarcoidosis | in blood↓, | in blood CD69/PD-1↑ | in blood IL-18↑ | |
| CF | in blood↓ | ND | ND | |
| Cancer | in blood↓ | in blood CCR6/CXCR6↑, CCR9↓ | in blood granzyme B/CD107a↑, |
COPD, Chronic obstructive pulmonary disease; CAP, Community-acquired pneumonia; COVID-19, coronavirus disease 2019; TB, tuberculosis; CF, cystic fibrosis; BALF, bronchoalveolar lavage fluid; IL, interleukin; CXCR, chemokine CXC receptor; PD-1, programmed death protein 1; DDIT3, DNA damage inducible transcript 3; HLA-DR, human leukocyte antigen DR; CCR, chemokine CC receptor; γc receptor, γ-chain receptor; TIM-3, T cell immunoglobulin domain and mucin domain-containing 3; IL4I1, interleukin-4-induced gene 1; IFN-γ, interferon-γ; TNF-α, tumor necrosis factor-α; MCP-1, monocyte chemotactic protein-1; MIP-1α, macrophage inflammatory protein-1α; PLZF, promyelocytic leukemia zinc finger; MAIT cell, mucosal-associated invariant T cell; ND, not determined; ↑increase; ↓decrease; ↑/↓mix response; –comparable.
Fig. 2MAIT cells in lung diseases. In asthma, MAIT cells have a protective effect against chronic inflammation while production of IL-17 is associated with disease severity. In COPD, MAIT cells are associated with disease severity too, and corticosteroid use inhibits MAIT cells in patients with COPD. In pneumonia, inflammatory factors derived from CD14+ monocytes promote the differentiation of MAIT cells producing IL-17 and inflammation. In tuberculosis, MAIT cells are protective against infection and impaired in immune response. In pulmonary sarcoidosis, MAIT cells present as exhaustion and activation phenotype that also reflect disease activity. In cystic fibrosis pulmonary disease, MAIT cells deficiency are related to pulmonary exacerbation and pseudomonas aeruginosa. In lung cancer, MAIT cells have potential to kill cancer cells, as well as MAIT cells defects are associated with cancer staging. CCR6, chemokine CC receptor 6; COPD, chronic obstructive pulmonary disease; CXCR6, chemokine CXC receptor 6; IFN-γ, interferon-γ; IL-17, interleukin-17; MAIT cell, mucosal-associated invariant T cell; PD-1, programmed death protein 1.